Loading...
Loading...
Momenta Pharmaceuticals,
Inc.
, a biotechnology company specializing in the
characterization and engineering of complex drugs, will present its approach
to designing novel therapeutics by applying site-specific sialylation to Fc
glycans in IVIg, monoclonal antibodies, and other recombinant Fc-containing
proteins, in a presentation entitled "Embracing Complexity: Understanding IVIg
to Rationally Engineer Novel Therapeutics". The presentation will be given by
Tony Manning, Ph.D., Vice President of Research at Momenta, at 12:10 pm on
Monday, May 5, 2014 at the PEGS annual meeting in Boston.
Momenta has thoroughly characterized a wide range of IVIg preparations to
understand the detailed composition of this plasma-derived product. Using
molecular, cellular, and animal models of disease, supplemented by an analysis
of samples from human patients treated with IVIg, the company has developed a
detailed understanding of the biological basis for the therapeutic effects of
IVIg. Momenta scientists now have a broad and comprehensive understanding of
the composition of IVIg and its mechanism of action as an anti-inflammatory
therapeutic. This research has informed the company's approach to the rational
design of several novel, differentiated therapeutic agents.
Momenta has also optimized the process for applying site-specific sialylation
to Fc glycans in antibodies, including IVIg and monoclonal antibodies, as well
as other recombinant Fc-containing proteins. In his presentation, Dr. Manning
will present data that demonstrate the enhanced anti-inflammatory activity of
these sialylated agents across a broad range of animal models of autoimmune
disease, including inflammatory arthritis, immune thrombocytopenic purpura
(ITP), pemphigus, and experimental autoimmune encephalomyelitis (EAE).
Finally, Dr. Manning will discuss how this research has led to approaches for
rationally engineering other novel recombinant product candidates which
display potential as broad anti-inflammatory therapeutics.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in